Under the traditional development model, advancing a drug from target discovery to a pre-clinical candidate takes an average ...
Generative biology is moving from code to the clinic, promising faster drug discovery while raising hard questions about safety, proof and control.
This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...
On June 24, 2026, the U.S. Food and Drug Administration (FDA) released a draft update to its 2019 draft guidance titled “Demonstrating ...
Announcing a new article publication for BIO Integration journal. Clinical trials bridge basic research and clinical application, serving as essential steps in drug development. This review examines ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit discusses what she learned at the inaugural AACR Drug Discovery ...
The Experimental Drug Development Center (EDDC), Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase I trial ...
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of cheaper, safer pharmaceuticals as well as alleviating animal suffering. But ...
While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset ...
Most anticancer drugs that enter clinical testing in children and adolescents fail to reach late-phase trials or earn pediatric regulatory approval, according to the authors of new research. Over a 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results